Bio-Rad Appoints Simon May Executive Vice President and Life Science Group President
16 Dezembro 2021 - 10:00AM
Business Wire
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader
of life science research and clinical diagnostic products, today
announced the appointment of Simon May as Executive Vice President
and President of the Life Science Group, effective January 4, 2022.
He succeeds Annette Tumolo who will retire from this role at that
time. Dr. May will be responsible for providing leadership and
management of the overall strategy and business direction for the
company’s Life Science Group global operations.
"We are pleased to promote Simon and believe that his strong
experience and expertise, coupled with his strengths in building
high-performing teams at Bio-Rad, make him ideally suited for this
important position," said Andrew Last, Bio-Rad Executive Vice
President and Chief Operating Officer. “We would also like to thank
Annette for her many years of valuable contributions to the growth
and success of Bio-Rad, and we wish her the best in her
retirement," Dr. Last said.
Dr. May has spent the last two years leading Bio-Rad’s Digital
Biology Group through significant growth and change, including the
integration of two acquisitions, IP litigation and several product
launches. Prior to his role within DBG, he served as SVP, Global
Commercial Operations, Americas with oversight of a $1 billion
business and more than 1,000 employees. Dr. May joined Bio-Rad in
September 2014 as VP, North America Sales & Service for Life
Science.
Prior to joining Bio-Rad, Dr. May spent seven years at Thermo
Fisher Scientific in various leadership roles in Sales and
Product/Portfolio Management. He holds a PhD in Molecular Biology
and acquired hands-on expertise in molecular biology and tissue
culture techniques as a Postdoctoral Research Fellow at the
University of Liverpool.
About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE: BIO and
BIOb) is a global leader in developing, manufacturing, and
marketing a broad range of innovative products for the life science
research and clinical diagnostic markets. With a focus on quality
and customer service for over 65 years, our products advance the
discovery process and improve healthcare. Our customers are
university and research institutions, hospitals, public health and
commercial laboratories, biotechnology and pharmaceutical
companies, as well as applied laboratories that include food safety
and environmental quality. Founded in 1952, Bio-Rad is based in
Hercules, California, and has a global network of operations with
more than 7,800 employees worldwide. Bio-Rad had revenues exceeding
$2.5 billion in 2020. For more information, please visit
bio-rad.com.
This release may be deemed to contain certain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include,
without limitation, statements we make regarding the expected
contributions and benefits of the new officer. We have based these
statements on the information now known to us. Such statements
involve risks and uncertainties, which could cause actual results
to vary materially from those expressed in or indicated by the
forward-looking statements. For further information regarding our
risks and uncertainties, please refer to the "Risk Factors" and
"Management's Discussion and Analysis of Financial Condition and
Results of Operation" in Bio-Rad’s public reports filed with the
Securities and Exchange Commission, including our most recent
Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q.
The Company cautions you not to place undue reliance on
forward-looking statements, which reflect an analysis only and
speak only as of the date hereof. Bio-Rad Laboratories, Inc.
disclaims any obligation to update these forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211216005275/en/
Investor Contact: Bio-Rad Laboratories, Inc. Edward
Chung, Vice President, Investor Relations 510-741-6577
ir@bio-rad.com
Bio Rad Laboratories (NYSE:BIO)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Bio Rad Laboratories (NYSE:BIO)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024